RxDoctor Payments Data

Gilberto Rodrigues, MD

Medical Oncology · Lake City, FLNPI 1700851243

Payments from drug & device makers

$1,793in general payments, 2019–2025

Across 89 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$253
  • Genentech USA, Inc.$161
  • Johnson & Johnson$149
  • Exelixis Inc.$125
  • Daiichi Sankyo Inc.$74
  • Gilead$71
  • plus $961 from 32 others

What the payments were for

  • Food & beverage$1,63991%
  • Education$1549%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,793 in reported general payments places this provider in the 15th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$4,344,665
Medicare patients
466
Services billed
205,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$315,621
XtandiEnzalutamide19$242,485
CalquenceAcalabrutinib Maleate15$229,639
BesremiRopeginterferon Alfa-2b-Njft13$226,625
ImbruvicaIbrutinib13$207,414
VenclextaVenetoclax20$147,165
LynparzaOlaparib13$120,333
EliquisApixaban72$60,650
Xtampza ErOxycodone Myristate19$11,296
Oxycodone Hcl98$1,548
Fentanyl12$1,160
Ondansetron OdtOndansetron68$1,058
Prochlorperazine Maleate65$1,048
Tamoxifen Citrate40$999
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence, Lynparza$25$349,97228 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$39$315,62125 claims
Astellas Pharma US IncXtandi$18$242,48519 claims
Pharmaessentia USA CorporationBesremi$17$226,62513 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$28$207,41413 claims
AbbVieVenclexta$51$147,16520 claims
PfizerEliquis$63$60,65072 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Lake City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →